Sepsis induced by cecal ligation and puncture

Methods in Molecular Biology

Volumn 1031, Issue , 2013, Pages 117-124

  Wen, Haitao ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Cecal ligation and puncture; CLP; Cytokine; Macrophage; Sepsis

Indexed keywords

CYTOKINE; ENDOTOXIN;

ABDOMINAL ABSCESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CECUM; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LIGATION; MACROPHAGE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PERITONEAL CAVITY; PERITONITIS; PRIORITY JOURNAL; SEPSIS; SURGICAL TECHNIQUE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; LIGATION; MICE; PERITONEAL CAVITY; PERITONITIS; PUNCTURES; SEPSIS;

EID: 84880340459     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-481-4_15     Document Type: Article

References (40)

1. Glauser MP, Zanetti G, Baumgartner JD, Cohen J (1991) Septic shock: Pathogenesis. Lancet 338:732-736
2. Parrillo JE (1993) Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477
3. Opal SM, Cohen J (1999) Clinical grampositive sepsis: Does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 27:1608-1616
4. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310
5. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546-1554
6. Geerdes HF, Ziegler D, Lode H, Hund M, Loehr A, Fangmann W, Wagner J (1992) Septicemia in 980 patients at a university hospital in Berlin: Prospective studies during 4 selected years between 1979 and 1989. Clin Infect Dis 15:991-1002
7. Van Amersfoort ES, Van Berkel TJ, Kuiper J (2003) Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16:379-414
8. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ ACCP/ATS/SIS international sepsis defi nitions conference. Intensive Care Med 29: 530-538
9. Riedemann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invest 112: 460-467
10. Tschoeke SK, Oberholzer A, Moldawer LL (2006) Interleukin-18: A novel prognostic cytokine in bacteria-induced sepsis. Crit Care Med 34:1225-1233
11. Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D (2003) Cytokine cascade in sepsis. Scand J Infect Dis 35:535-544
12. Lin WJ, Yeh WC (2005) Implication of tolllike receptor and tumor necrosis factor alpha signaling in septic shock. Shock 24:206-209
13. Lin KJ, Lin J, Hanasawa K, Tani T, Kodama M (2000) Interleukin-8 as a predictor of the severity of bacteremia and infectious disease. Shock 14:95-100
14. Coelho AL, Hogaboam CM, Kunkel SL (2005) Chemokines provide the sustained infl ammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev 16:553-560
15. Horn KD (1998) Evolving strategies in the treatment of sepsis and systemic infl ammatory response syndrome (SIRS). Qjm 91:265-277
16. Karima R, Matsumoto S, Higashi H, Matsushima K (1999) The molecular pathogenesis of endotoxic shock and organ failure. Mol Med Today 5:123-132
17. Riedemann NC, Guo RF, Ward PA (2003) Novel strategies for the treatment of sepsis. Nat Med 9:517-524
18. Davis CE, Brown KR, Douglas H, Tate WJ 3rd, Braude AI (1969) Prevention of death from endotoxin with antisera. I. The risk of fatal anaphylaxis to endotoxin. J Immunol 102:563-572
19. Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869-871
20. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ 3rd, Zentella A, Albert JD et al (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234:470-474
21. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-664
22. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552
23. Cohen J (1999) Adjunctive therapy in sepsis: A critical analysis of the clinical trial programme. Br Med Bull 55:212-225
24. Reinhart K, Karzai W (2001) Anti-Tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned. Crit Care Med 29:S121-S125
25. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E (1996) Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697-1702
26. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL et al (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271:1836-1843
27. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA et al (1997) Confi rmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25: 1115-1124
28. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
29. Deitch EA (1998) Animal models of sepsis and shock: A review and lessons learned. Shock 9:1-11
30. Parker SJ, Watkins PE (2001) Experimental models of gram-negative sepsis. Br J Surg 88:22-30
31. Esmon CT (2004) Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 32:S219-222
32. Maier S, Traeger T, Entleutner M, Westerholt A, Kleist B, Huser N, Holzmann B, Stier A, Pfeffer K, Heidecke CD (2004) Cecal ligation and puncture versus colon ascendens stent peritonitis: Two distinct animal models for polymicrobial sepsis. Shock 21:505-511
33. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW 3rd, Bland KI, Chaudry IH (2005) Cecal ligation and puncture. Shock 24(Suppl 1):52-57
34. Walley KR, Lukacs NW, Standiford TJ, Strieter RM, Kunkel SL (1996) Balance of infl amatory cytokines related to severity and mortality of murine sepsis. Infect Immun 64:4733-4738
35. Radojicic C, Andric B, Simovic M, Dujic A, Marinkovic D (1990) Genetic basis of resistance to trauma in inbred strains of mice. J Trauma 30:211-213
36. von Stebut E, Udey MC (2004) Requirements for Th1-dependent immunity against infection with Leishmania major. Microbes Infect 6:1102-1109
37. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2:845-858
38. Benjamim CF, Hogaboam CM, Lukacs NW, Kunkel SL (2003) Septic mice are susceptible to pulmonary aspergillosis. Am J Pathol 163:2605-2617
39. Benjamim CF, Lundy SK, Lukacs NW, Hogaboam CM, Kunkel SL (2005) Reversal of long-Term sepsis-induced immunosuppression by dendritic cells. Blood 105: 3588-3595
40. Wen H, Hogaboam CM, Gauldie J, Kunkel SL (2006) Severe sepsis exacerbates cell-mediated immunity in the lung due to an altered dendritic cell cytokine profile. Am J Pathol 168:1940-1950